Literature DB >> 30968699

Is 30-day readmission an accurate measure of morbidity in cranial meningioma surgery?

Zoe James1, Paul A Leach1, Caroline Hayhurst1.   

Abstract

Introduction: 30-day readmission rate is a widely adopted marker of quality and performance of acute care, but validity is not well demonstrated. Readmission data following cranial meningioma surgery is not well described and we sought to assess risk factors for readmission. Subjects: All adult patients who underwent cranial meningioma resection from January 2015 to December 2017 in a single institution.
Methods: Using Welsh Clinical Portal electronic data to identify readmission within and beyond 30 days to both the index hospital and regional hospitals. Causes of readmission were recorded.
Results: 160 patients were included (76.3% female, median age 58, age range 23-78). 28 cases (17.5%) were emergency admissions, median length of initial admission 7 days. 42 patients (26.3%) had seizures at presentation. Total readmission rate was 13.8% (median age 54.5, pre-operative seizure rate 40.9%, median length of readmission 9 days). 13 (59.1%) patients presented within 30 days and 9 (40.9%) >30 days. Readmission causes were seizure, neurological deficit, thromboembolic, infection, CSF, bleeding and social. Causes after 30 days were the same except social or neurological deficit. Discussion: Readmission rates are not associated with age, tumour location, tumour grade, admission route or initial length of stay. 40.9% of readmissions presented outside of the 30-day post-operative time. 30-day readmission rates may not be the most suitable method to demonstrate neurosurgical unit performance in meningioma surgery.

Entities:  

Keywords:  30-day readmission; Readmission; craniotomy; meningioma

Mesh:

Year:  2019        PMID: 30968699     DOI: 10.1080/02688697.2019.1600658

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  2 in total

1.  Impact of insurance on hospital course and readmission after resection of benign meningioma.

Authors:  Blake M Hauser; Saksham Gupta; Edward Xu; Kyle Wu; Joshua D Bernstock; Melissa Chua; Ayaz M Khawaja; Timothy R Smith; Ian F Dunn; Regan W Bergmark; Wenya Linda Bi
Journal:  J Neurooncol       Date:  2020-07-11       Impact factor: 4.130

2.  Critical appraisal of minimally invasive keyhole surgery for intracranial meningioma in a large case series.

Authors:  Jai Deep Thakur; Regin Jay Mallari; Alex Corlin; Samantha Yawitz; Amalia Eisenberg; John Rhee; Walavan Sivakumar; Howard Krauss; Neil Martin; Chester Griffiths; Garni Barkhoudarian; Daniel F Kelly
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.